A clinical study on the safety of comprehensive therapy against hepatocarcinoma: combination of TAE and RFA , dendric cell
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000036065
- Lead Sponsor
- Juntendo University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Not provided
1) Patients must not have heart disorder, kidney disorder, respiratory disorder, hematopathy, clotting disorder, or other serious complication. 2) Patients must not be HIV positive. 3) Patients must not have carcinoma nor immunodeficiency in past history. 4) Patients must not have splenectomy nor splen radiation in past history. 5) Patients must not have allo organ transplantation in past history. 6) Patients must not subjected to continuous whole body administration of adrenal cortical steroid or antihistaminic. 7) Patients must have no surgery, chemotherapy nor radiation within 4 weeks before blood collection for treatment in this study. In addition, patients are also excluded if they have not recovered enough from those therapies above. 8) Female patients are excluded from the study when they are pregnant, possibly pregnant, or when they want to be pregnant or they are feeding. 9) Patients must be excluded when expected to be difficult to follow-up. 10) Patients must be excluded when principal investigator judge as inadequate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety Safety is assessed at the first blood collection for cell preparation and from TAE to two weeks after RFA.
- Secondary Outcome Measures
Name Time Method Efficacy Recurrence-free survival time is evaluated by image diagnosis after RFA.